Probiotics: If it does not help it does not do any harm. really?

Microorganisms

Volumn 7, Issue 4, 2019, Pages

  Lerner, Aaron ^a,b   Shoenfeld, Yehuda ^c   Matthias, Torsten ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b AESKUKIPP Institute   (Germany)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Antibiotic resistant genes; Autoimmune disease; Horizontal gene transfer; Probiotics; Public health; Virulent factor

Indexed keywords

EID: 85074135291     PISSN: None     EISSN: 20762607     Source Type: Journal    
DOI: 10.3390/microorganisms7040104     Document Type: Article

References (213)

1. Doré, J.; Multon, M.C.; Béhier, J.M.; Affagard, H.; Andremont, A.; Barthélémy, P.; Batitsa, R.; Bonneville, M.; Bonny, C.; Boyaval, G.; et al. The human gut microbiome as source of innovation for health: Which physiological and therapeutic outcomes could we expect? Therapie 2017, 72, 21–38. [CrossRef]
2. Glendinning, L.; Free, A. Supra-organismal interactions in the human intestine. Front. Cell. Infect. Microbiol. 2014, 4, 47. [CrossRef] [PubMed]
3. Nicholson, J.K.; Holmes, E.; Wilson, I.D. Gut microorganisms, mammalian metabolism and personalized health care. Nat. Rev. Microbiol. 2005, 3, 431–438. [CrossRef] [PubMed]
4. Lerner, A.; Matthias, T. GUT-the Trojan horse in remote organs’ autoimmunity. J. Clin. Cell. Immunol. 2016, 7, 401.
5. Lerner, A.; Neidhöfer, S.; Matthias, T. The gut microbiome feelings of the brain: Perspective for Non-Microbiologists. Microorganisms 2017, 5, 66. [CrossRef]
6. Harari, Y.N. Sapiens: A Brief History of Humankind; Vintage Books: London, UK, 2011; pp. 1–466.
7. Lerner, A. The last two millennias eco-catastrophes are the driving forces for the potential genetic advantage mechanisms in celiac disease. Med. Hypotheses 2011, 77, 773–776.
8. Lerner, A.; Aminov, R.; Matthias, T. Potential effects of horizontal gene exchange in the human gut. Front. Microbiol. 2017, 8, 1630. [CrossRef]
9. Lerner, A.; Aminov, R.; Matthias, T. Dysbiosis may trigger autoimmune diseases via inappropriate posttranslational modification of host proteins. Front. Microbiol. 2016, 7, 84. [CrossRef]
10. Ozen, M.; Dinleyici, E.C. The history of probiotics: The untold story. Benef. Microbes 2015, 6, 159–165. [CrossRef] [PubMed]
11. Gasbarrini, G.; Bonvicini, F.; Gramenzi, A. Probiotics History. In Proceedings of the 8th Probiotics, Prebiotics & New Foods for Microbiota and Human Health Meeting, Rome, Italy, 13–15 September 2015; pp. S116–S119.
12. Villena, J.; Kitazawa, H. Probiotic Microorganisms: A Closer Look. Microorganisms 2017, 5, 17. [CrossRef]
13. Liu, Y.; Alookaran, J.J.; Rhoads, J.M. Probiotics in Autoimmune and Inflammatory Disorders. Nutrients 2018, 10, 1537. [CrossRef]
14. Mathipa, M.G.; Thantsha, M.S. Probiotic engineering: Towards development of robust probiotic strains with enhanced functional properties and for targeted control of enteric pathogens. Gut Pathog. 2017, 9, 28. [CrossRef]
15. Liu, Y.; Tran, D.Q.; Rhoads, J.M. Probiotics in Disease Prevention and Treatment. J. Clin. Pharmacol. 2018, 58 (Suppl. 10), S164–S179. [CrossRef]
16. Pirbaglou, M.; Katz, J.; de Souza, R.J.; Stearns, J.C.; Motamed, M.; Ritvo, P. Probiotic supplementation can positively affect anxiety and depressive symptoms: A systematic review of randomized controlled trials. Nutr. Res. 2016, 36, 889–898. [CrossRef]
17. Saxelin, M. Probiotic formulations and applications, the current probiotics market, and changes in the marketplace: A European perspective. Clin. Infect. Dis. 2008, 46 (Suppl. 2), S76–S79; discussion S144–S151. [CrossRef]
18. Di Cerbo, A.; Palmieri, B. Review: The market of probiotics. Pak. J. Pharm. Sci. 2015, 28, 2199–2206.
19. Reid, G.; Kort, R.; Alvarez, S.; Bourdet-Sicard, R.; Benoit, V.; Cunningham, M.; Saulnier, D.; Vlieg, J.V.H.; Verstraelen, H.; Sybesma, W. Expanding the reach of probiotics through social enterprises. Benef. Microbes 2018, 9, 707–715. [CrossRef]
20. Glendinning, L.; Free, A. Supra-organismal interactions in the human intestine. Front. Cell. Infect. Microbiol. 2014, 4, 47. [CrossRef] [PubMed]
21. Glendinning, L.; Free, A. Supra-organismal interactions in the human intestine. Front. Cell. Infect. Microbiol. 2014, 4, 47. [CrossRef] [PubMed]
22. de Vrese, M.; Schrezenmeir, J. Probiotics, prebiotics, and synbiotics. Adv. Biochem. Eng. Biotechnol. 2008, 111, 1–66. [CrossRef]
23. Goldin, B.R.; Gorbach, S.L. Clinical indications for probiotics: An overview. Clin. Infect. Dis. 2008, 46 (Suppl. 2), S96–S100; discussion S144–S151. [CrossRef]
24. Minocha, A. Probiotics for preventive health. Nutr. Clin. Pract. 2009, 24, 227–241. [CrossRef]
25. D’Angelo, C.; Reale, M.; Costantini, E. Microbiota and Probiotics in Health and HIV Infection. Nutrients 2017, 9, 615. [CrossRef]
26. Westfall, E.; Brandenburg, D. Probiotics for Symptoms of Depression and Anxiety. Am. Fam. Phys. 2018, 97. online.
27. Lieske, J.C. Probiotics for prevention of urinary stones. Ann. Transl. Med. 2017, 5, 29. [CrossRef]
28. Misra, S.; Medhi, B. Role of probiotics as memory enhancer. Indian J. Pharmacol. 2013, 45, 311–312. [CrossRef]
29. Chong, H.X.; Yusoff, N.A.A.; Hor, Y.Y.; Lew, L.C.; Jaafar, M.H.; Choi, S.B.; Yusoff, M.; Wahid, N.; Abdullah, M.; Zakaria, N.; et al. Lactobacillus plantarum DR7 alleviates stress and anxiety in adults: A randomised, double-blind, placebo-controlled study. Benef. Microbes 2019, 18, 1–20. [CrossRef]
30. Gorbach, S.L. Probiotics in the third millennium. Dig. Liver Dis. 2002, 34 (Suppl. 2), S2–S7. [CrossRef]
31. Mahmoodpoor, A.; Hamishehkar, H.; Asghari, R.; Abri, R.; Shadvar, K.; Sanaie, S. Effect of a Probiotic Preparation on Ventilator-Associated Pneumonia in Critically Ill Patients Admitted to the Intensive Care Unit: A Prospective Double-Blind Randomized Controlled Trial. Nutr. Clin. Pract. 2019, 34, 156–162. [CrossRef]
32. Sohn, K.; Underwood, M.A. Prenatal and postnatal administration of prebiotics and probiotics. Semin. Fetal Neonatal Med. 2017, 22, 284–289. [CrossRef]
33. Ayala, F.R.; Bauman, C.; Cogliati, S.; Leñini, C.; Bartolini, M.; Grau, R. Microbial flora, probiotics, Bacillus subtilis and the search for a long and healthy human longevity. Microb. Cell 2017, 4, 133–136. [CrossRef]
34. Guslandi, M. Role of Probiotics in Crohn’s Disease and in Pouchitis. J. Clin. Gastroenterol. 2015, 49 (Suppl. 1), S46–S49. [CrossRef]
35. Tirandaz, H.; Ebrahim-Habibi, M.B.; Moradveisi, B.; Raoofi, S.; Salehi-Najafabadi, A.; Mohammadi, E. Microbiota potential for the treatment of sexual dysfunction. Med. Hypotheses 2018, 115, 46–49. [CrossRef]
36. Ahtesh, F.B.; Stojanovska, L.; Apostolopoulos, V. Anti-hypertensive peptides released from milk proteins by probiotics. Maturitas 2018, 115, 103–109. [CrossRef]
37. Santocchi, E.; Guiducci, L.; Fulceri, F.; Billeci, L.; Buzzigoli, E.; Apicella, F.; Calderoni, S.; Grossi, E.; Morales, M.A.; Muratori, F. Gut to brain interaction in Autism Spectrum Disorders: A randomized controlled trial on the role of probiotics on clinical, biochemical and neurophysiological parameters. BMC Psychiatry 2016, 16, 183. [CrossRef]
38. Welcome, M.O. Current Perspectives and Mechanisms of Relationship between Intestinal Microbiota Dysfunction and Dementia: A Review. Dement. Geriatr. Cogn. Dis. Extra 2018, 8, 360–381. [CrossRef]
39. Bezirtzoglou, E.; Stavropoulou, E. Immunology and probiotic impact of the newborn and young children intestinal microflora. Anaerobe 2011, 17, 369–374. [CrossRef]
40. Khoruts, A. Targeting the microbiome: From probiotics to fecal microbiota transplantation. Genome Med. 2018, 10, 80. [CrossRef]
41. Rao, S.S.C.; Rehman, A.; Yu, S.; Andino, N.M. Brain fogginess, gas and bloating: A link between SIBO, probiotics and metabolic acidosis. Clin. Transl. Gastroenterol. 2018, 9, 162. [CrossRef]
42. Zmora, N.; Zilberman-Schapira, G.; Suez, J.; Mor, U.; Dori-Bachash, M.; Bashiardes, S.; Kotler, E.; Zur, M.; Regev-Lehavi, D.; Brik, R.B.-Z.; et al. Personalized Gut Mucosal Colonization Resistance to Empiric Probiotics Is Associated with Unique Host and Microbiome Features. Cell 2018, 174, 1388–1405. [CrossRef]
43. Suez, J.; Zmora, N.; Zilberman-Schapira, G.; Mor, U.; Dori-Bachash, M.; Bashiardes, S.; Zur, M.; Regev-Lehavi, D.; Brik, R.B.-Z.; Federici, S.; et al. Post-Antibiotic Gut Mucosal Microbiome Reconstitution Is Impaired by Probiotics and Improved by Autologous FMT. Cell 2018, 174, 1406–1423. [CrossRef]
44. Singh, A.; Sarangi, A.N.; Goel, A.; Srivastava, R.; Bhargava, R.; Gaur, P.; Aggarwal, A.; Aggarwal, R. Effect of administration of a probiotic preparation on gut microbiota and immune response in healthy women in India: An open-label, single-arm pilot study. BMC Gastroenterol. 2018, 18, 85. [CrossRef]
45. Derrien, M.; van Hylckama Vlieg, J.E. Fate, activity, and impact of ingested bacteria within the human gut microbiota. Trends Microbiol. 2015, 23, 354–366. [CrossRef]
46. Maldonado-Gómez, M.X.; Martínez, I.; Bottacini, F.; O’Callaghan, A.; Ventura, M.; van Sinderen, D.; Hillmann, B.; Vangay, P.; Knights, D.; Hutkins, R.W.; et al. Stable Engraftment of Bifidobacterium longum AH1206 in the Human Gut Depends on Individualized Features of the Resident Microbiome. Cell Host Microbe 2016, 20, 515–526. [CrossRef]
47. Laursen, M.F.; Laursen, R.P.; Larnkjær, A.; Michaelsen, K.F.; Bahl, M.I.; Licht, T.R. Administration of two probiotic strains during early childhood does not affect the endogenous gut microbiota composition despite probiotic proliferation. BMC Microbiol. 2017, 17, 175. [CrossRef]
48. Kristensen, N.B.; Bryrup, T.; Allin, K.H.; Nielsen, T.; Hansen, T.H.; Pedersen, O. Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: A systematic review of randomized controlled trials. Genome Med. 2016, 8, 52. [CrossRef]
49. Selmi, C.; Gao, B.; Gershwin, M.E. The long and latent road to autoimmunity. Cell. Mol. Immunol. 2018, 15, 543–546. [CrossRef]
50. De Luca, F.; Shoenfeld, Y. The microbiome in autoimmune diseases. Clin. Exp. Immunol. 2019, 195, 74–85. [CrossRef]
51. Haase, S.; Haghikia, A.; Wilck, N.; Müller, D.N.; Linker, R.A. Impacts of microbiome metabolites on immune regulation and autoimmunity. Immunology 2018, 154, 230–238. [CrossRef]
52. Chen, B.; Sun, L.; Zhang, X. Integration of microbiome and epigenome to decipher the pathogenesis of autoimmune diseases. J. Autoimmun. 2017, 83, 31–42. [CrossRef]
53. de Oliveira, G.L.V.; Leite, A.Z.; Higuchi, B.S.; Gonzaga, M.I.; Mariano, V.S. Intestinal Dysbiosis and pRobiotic Applications in Autoimmune Diseases. Immunology 2017, 152, 1–12. [CrossRef]
54. de Oliveira, G.L.V. Probiotic applications in autoimmune diseases In Probiotics-Current Knowledge and Future Prospects; IntechOpen: London, UK, 2018; pp. 69–89.
55. Marietta, E.; Horwath, I.; Balakrishnan, B.; Taneja, V. Role of the intestinal microbiome in autoimmune diseases and its use in treatments. Cell Immunol. 2018. [CrossRef]
56. Balakrishnan, B.; Taneja, V. Microbial modulation of the gut microbiome for treating autoimmune diseases. Expert Rev Gastroenterol. Hepatol. 2018, 12, 985–996. [CrossRef]
57. Dwivedi, M.; Kumar, P.; Laddha, N.C.; Kemp, E.H. Induction of regulatory T cells: A role for probiotics and prebiotics to suppress autoimmunity. Autoimmun. Rev. 2016, 15, 379–392. [CrossRef]
58. Tankou, S.K.; Regev, K.; Healy, B.C.; Cox, L.M.; Tjon, E.; Kivisakk, P.; Vanande, I.P.; Cook, S.; Gandhi, R.; Glanz, B.; et al. Investigation of probiotics in multiple sclerosis. Mult. Scler. 2018, 24, 58–63. [CrossRef]
59. Kota, R.K.; Ambati, R.R.; Yalakurthi, A.K.; Srirama, K.; Reddy, P.N. Recent advances in probiotics as live biotherapeutics against gastrointestinal diseases. Curr. Pharm. Des. 2018, 24, 3162–3171. [CrossRef]
60. Eom, T.; Kim, Y.S.; Choi, C.H.; Sadowsky, M.J.; Unno, T. Current understanding of microbiota-and dietary-therapies for treating inflammatory bowel disease. J. Microbiol. 2018, 56, 189–198. [CrossRef]
61. Rinaldi, E.; Consonni, A.; Guidesi, E.; Elli, M.; Mantegazza, R.; Baggi, F. Gut microbiota and probiotics: Novel immune system modulators in myasthenia gravis? Ann. N. Y. Acad. Sci. 2018, 1413, 49–58. [CrossRef]
62. Aqaeinezhad Rudbane, S.M.; Rahmdel, S.; Abdollahzadeh, S.M.; Zare, M.; Bazrafshan, A.; Mazloomi, S.M. The efficacy of probiotic supplementation in rheumatoid arthritis: A meta-analysis of randomized, controlled trials. Inflammopharmacology 2018, 26, 67–76. [CrossRef]
63. Aminov, R.I. The extent and regulation of lateral gene transfer in natural microbial ecosystems. In Horizontal Gene Transfer in Microorganisms; Francino, M.P., Ed.; Horizon Scientific Press: Norwich, UK, 2012; Chapter 6; pp. 93–100.
64. Wong, A.; Ngu, D.Y.; Dan, L.A.; Ooi, A.; Lim, R.L. Detection of antibiotic resistance in probiotics of dietary supplements. Nutr. J. 2015, 14, 95. [CrossRef]
65. Zheng, M.; Zhang, R.; Tian, X.; Zhou, X.; Pan, X.; Wong, A. Assessing the Risk of Probiotic Dietary Supplements in the Context of Antibiotic Resistance. Front. Microbiol. 2017, 8, 908. [CrossRef]
66. van Reenen, C.A.; Dicks, L.M. Horizontal gene transfer amongst probiotic lactic acid bacteria and other intestinal microbiota: What are the possibilities? A review. Arch. Microbiol. 2011, 193, 157–168. [CrossRef]
67. Mercanti, D.J.; Rousseau, G.M.; Capra, M.L.; Quiberoni, A.; Tremblay, D.M.; Labrie, S.J.; Moineau, S. Genomic Diversity of Phages Infecting Probiotic Strains of Lactobacillus paracasei. Appl. Environ. Microbiol. 2015, 82, 95–105. [CrossRef]
68. Ceapa, C.; Davids, M.; Ritari, J.; Lambert, J.; Wels, M.; Douillard, F.P.; Smokvina, T.; De Vos, W.M.; Knol, J.; Kleerebezem, M. The Variable Regions of Lactobacillus rhamnosus Genomes Reveal the Dynamic Evolution of Metabolic and Host-Adaptation Repertoires. Genome Biol. Evol. 2016, 8, 1889–1905. [CrossRef]
69. Tannock, G.W.; Luchansky, J.B.; Miller, L.; Connell, H.; Thode-Andersen, S.; Mercer, A.A.; Klaenhammer, T.R. Molecular characterization of a plasmid-borne (pGT633) erythromycin resistance determinant (ermGT) from Lactobacillus reuteri 100-63. Plasmid 1994, 31, 60–71. [CrossRef]
70. Lin, C.F.; Fung, Z.F.; Wu, C.L.; Chung, T.C. Molecular characterization of a plasmid-borne (pTC82) chloramphenicol resistance determinant (cat-TC) from Lactobacillus reuteri G4. Plasmid 1996, 36, 116–124. [CrossRef]
71. Egervärn, M.; Roos, S.; Lindmark, H. Identification and characterization of antibiotic resistance genes in Lactobacillus reuteri and Lactobacillus plantarum. J. Appl. Microbiol. 2009, 107, 1658–1668. [CrossRef]
72. Baugher, J.L.; Durmaz, E.; Klaenhammer, T.R. Spontaneously induced prophages in Lactobacillus gasseri contribute to horizontal gene transfer. Appl. Environ. Microbiol. 2014, 80, 3508–3517. [CrossRef]
73. Courvalin, P. Predictable and unpredictable evolution of antibiotic resistance. J. Intern. Med. 2008, 264, 4–16. [CrossRef]
74. Doron, S.; Snydman, D.R. Risk and safety of probiotics. Clin. Infect. Dis. 2015, 60 (Suppl. 2), S129–S134. [CrossRef]
75. Egervärn, M.; Lindmark, H.; Olsson, J.; Roos, S. Transferability of a tetracycline resistance gene from probiotic Lactobacillus reuteri to bacteria in the gastrointestinal tract of humans. Antonie Van Leeuwenhoek 2010, 97, 189–200. [CrossRef]
76. Imperial, I.C.; Ibana, J.A. Addressing the Antibiotic Resistance Problem with Probiotics: Reducing the Risk of Its Double-Edged Sword Effect. Front. Microbiol. 2016, 7, 1983. [CrossRef]
77. Rosander, A.; Connolly, E.; Roos, S. Removal of antibiotic resistance gene-carrying plasmids from Lactobacillus reuteri ATCC 55730 and characterization of the resulting daughter strain, L. reuteri DSM 17938. Appl. Environ. Microbiol. 2008, 74, 6032–6040. [CrossRef]
78. Muñoz-Atienza, E.; Gómez-Sala, B.; Araújo, C.; Campanero, C.; del Campo, R.; Hernández, P.E.; Herranz, C.; Cintas, L.M. Antimicrobial activity, antibiotic susceptibility and virulence factors of Lactic Acid Bacteria of aquatic origin intended for use as probiotics in aquaculture. BMC Microbiol. 2013, 13, 15. [CrossRef]
79. Fittipaldi, N.; Segura, M.; Grenier, D.; Gottschalk, M. Virulence factors involved in the pathogenesis of the infection caused by the swine pathogen and zoonotic agent Streptococcus suis. Future Microbiol. 2012, 7, 259–279. [CrossRef]
80. Yu, J.; Pian, Y.; Ge, J.; Guo, J.; Zheng, Y.; Jiang, H.; Hao, H.; Yuan, Y.; Jiang, Y.; Yang, M. Functional and Structural Characterization of the Antiphagocytic Properties of a Novel Transglutaminase from Streptococcus suis. J. Biol. Chem. 2015, 290, 19081–19092. [CrossRef]
81. Lerner, A.; Matthias, T. Changes in intestinal tight junction permeability associated with industrial food additives explain the rising incidence of autoimmune disease. Autoimmun. Rev. 2015, 14, 479–489. [CrossRef]
82. Lerner, A.; Matthias, T. Possible association between celiac disease and bacterial transglutaminase in food processing: A hypothesis. Nutr. Rev. 2015, 73, 544–552. [CrossRef]
83. Lerner, A.; Aminov, R.; Matthias, T. Intestinal dysbiotic transglutaminases are potential environmental drivers of systemic autoimmunogenesis. Front. Microbiol. 2017, 8, 66. [CrossRef]
84. Matthias, T.; Jeremias, P.; Neidhöfer, S.; Lerner, A. The industrial food additive microbial transglutaminase, mimics the tissue transglutaminase and is immunogenic in celiac disease patients. Autoimmun. Rev. 2016, 15, 1111–1119. [CrossRef]
85. Matthias, T.; Lerner, A. Microbial transglutaminase is immunogenic and potentially pathogenic in pediatric celiac disease. Front. Pediatr. 2018, 6, 389. [CrossRef]
86. Zhang, D.; de Souza, R.F.; Anantharaman, V.; Lyer, L.M.; Aravind, L. Polymorphic toxin systems: Comprehensive characterization of trafficking modes, processing, mechanisms of action, immunity and ecology using comparative genomics. Biol. Direct 2012, 7, 18. [CrossRef]
87. Masuda, M.; Betancourt, L.; Matsuzawa, T.; Kashimoto, T.; Takao, T.; Shimonishi, Y.; Horiguchi, Y. Activation of Rho through a cross-link with polyamines catalyzed by Bordetella dermonecrotizing toxin. EMBO J. 2000, 19, 521–530. [CrossRef]
88. Jubelin, G.; Chavez, C.V.; Taieb, F.; Banfield, M.J.; Samba-Louaka, A.; Nobe, R.; Nougayrède, J.-P.; Zumbihl, R.; Givaudan, A.; Escoubas, J.-M.; et al. Cycle Inhibiting Factors (CIFs) Are a Growing Family of Functional Cyclomodulins Present in Invertebrate and Mammal Bacterial Pathogens. PLoS ONE 2009, 4, e4855. [CrossRef]
89. Schmidt, G.; Selzer, J.; Lerm, M.; Aktories, K. The Rho-deamidating cytotoxic necrotizing factor 1 from Escherichia coli possesses transglutaminase activity. Cysteine 866 and histidine 881 are essential for enzyme activity. J. Biol. Chem. 1998, 273, 13669–13674. [CrossRef]
90. Makarova, K.S.; Aravind, L.; Koonin, E.V. A superfamily of archaeal, bacterial, and eukaryotic proteins homologous to animal transglutaminases. Protein Sci. 1999, 8, 1714–1719. [CrossRef]
91. Lerner, A.; Matthias, T. Microbial transglutaminase is beneficial to food industries but a caveat to public health. Med One 2019, 4, e190001. [CrossRef]
92. Sitaraman, R. Prokaryotic horizontal gene transfer within the human holobiont: Ecological-evolutionary inferences, implications and possibilities. Microbiome 2018, 6, 163. [CrossRef]
93. Xu, F.; Wang, J.; Guo, Y.; Fu, P.; Zeng, H.; Li, Z.; Pei, X.; Liu, X.; Wang, S. Antibiotic resistance, biochemical typing, and PFGE typing of Bifidobacterium strains commonly used in probiotic health foods. Food Sci. Biotechnol. 2018, 27, 467–477. [CrossRef]
94. Gueimonde, M.; Sánchez, B.; de Los Reyes-Gavilán, C.; Margolles, A. Antibiotic resistance in probiotic bacteria. Front. Microbiol. 2013, 4, 202. [CrossRef]
95. Comunian, R.; Daga, E.; Dupré, I.; Paba, A.; Devirgiliis, C.; Piccioni, V.; Perozzi, G.; Zonenschain, D.; Rebecchi, A.; Morelli, L.; et al. Susceptibility to tetracycline and erythromycin of Lactobacillus paracasei strains isolated from traditional Italian fermented foods. Int. J. Food Microbiol. 2010, 138, 151–156. [CrossRef]
96. Guo, H.; Pan, L.; Li, L.; Lu, J.; Kwok, L.; Menghe, B.; Zhang, H. Characterization of Antibiotic Resistance Genes from Lactobacillus Isolated from Traditional Dairy Products. J. Food Sci. 2017, 82, 724–730. [CrossRef]
97. Dec, M.; Nowaczek, A.; Stępień-Pyśniak, D.; Wawrzykowski, J.; Urban-Chmiel, R. Identification and antibiotic susceptibility of lactobacilli isolated from turkeys. BMC Microbiol. 2018, 18, 168. [CrossRef]
98. Agersø, Y.; Stuer-Lauridsen, B.; Bjerre, K.; Jensen, M.G.; Johansen, E.; Bennedsen, M.; Brockmann, E.; Nielsen, B. Antimicrobial Susceptibility Testing and Tentative Epidemiological Cutoff Values for Five Bacillus Species Relevant for Use as Animal Feed Additives or for Plant Protection. Appl. Environ. Microbiol. 2018, 84, e01108-18. [CrossRef]
99. Abriouel, H.; Casado Muñoz, M.D.C.; Lavilla Lerma, L.; Pérez Montoro, B.; Bockelmann, W.; Pichner, R.; Kabisch, J.; Cho, G.S.; Franz, C.M.A.P.; Gálvez, A.; et al. New insights in antibiotic resistance of Lactobacillus species from fermented foods. Food Res. Int. 2015, 78, 465–481. [CrossRef]
100. Vitetta, L.; Vitetta, G.; Hall, S. Immunological Tolerance and Function: Associations Between Intestinal Bacteria, Probiotics, Prebiotics, and Phages. Front. Immunol. 2018, 9, 2240. [CrossRef]
101. Bakhshinejad, B.; Ghiasvand, S. Bacteriophages in the human gut: Our fellow travelers throughout life and potential biomarkers of heath or disease. Virus Res. 2017, 240, 47–55. [CrossRef]
102. Tetz, G.; Tetz, V. Bacteriophages as New Human Viral Pathogens. Microorganisms 2018, 6, 54. [CrossRef]
103. Pfeiffer, J.K.; Virgin, H.W. Viral immunity. Transkingdom control of viral infection and immunity in the mammalian intestine. Science 2016, 351, aad5872. [CrossRef]
104. Proal, A.; Marshall, T. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in the Era of the Human Microbiome: Persistent Pathogens Drive Chronic Symptoms by Interfering With Host Metabolism, Gene Expression, and Immunity. Front. Pediatr. 2018. [CrossRef]
105. Tetz, G.; Tetz, V. Prion-Like Domains in Phagobiota. Front. Microbiol. 2017, 8, 2239. [CrossRef]
106. Muniesa, M.; Colomer-Lluch, M.; Jofre, J. Potential impact of environmental bacteriophages in spreading antibiotic resistance genes. Future Microbiol. 2013, 8, 739–751. [CrossRef]
107. Muniesa, M.; Colomer-Lluch, M.; Jofre, J. Could bacteriophages transfer antibiotic resistance genes from environmental bacteria to human-body associated bacterial populations? Mob. Genet. Elem. 2013, 3, e25847. [CrossRef]
108. Lood, R.; Ertürk, G.; Mattiasson, B. Revisiting Antibiotic Resistance Spreading in Wastewater Treatment Plants—Bacteriophages as a Much Neglected Potential Transmission Vehicle. Front. Microbiol. 2017, 8, 2298. [CrossRef]
109. Quirós, P.; Colomer-Lluch, M.; Martínez-Castillo, A.; Miró, E.; Argente, M.; Jofre, J.; Navarro, F.; Muniesa, M. Antibiotic resistance genes in the bacteriophage DNA fraction of human fecal samples. Antimicrob. Agents Chemother. 2014, 58, 606–609. [CrossRef]
110. Eaton, T.J.; Gasson, M.J. Molecular screening of Enterococcus virulence determinants and potential for genetic exchange between food and medical isolates. Appl. Environ. Microbiol. 2001, 67, 1628–1635. [CrossRef]
111. Marcó, M.B.; Moineau, S.; Quiberoni, A. Bacteriophages and dairy fermentations. Bacteriophage 2012, 2, 149–158. [CrossRef]
112. Domingo-Calap, P.; Delgado-Martínez, J. Bacteriophages: Protagonists of a Post-Antibiotic Era. Antibiotics 2018, 7, 66. [CrossRef]
113. Li, J.; Cao, J.; Zhu, Y.G.; Chen, Q.L.; Shen, F.; Wu, Y.; Xu, S.; Fan, H.; Da, G.; Huang, R.-J.; et al. Global Survey of Antibiotic Resistance Genes in Air. Environ. Sci. Technol. 2018, 52, 10975–10984. [CrossRef]
114. Villion, M.; Moineau, S. Bacteriophages of lactobacillus. Front. Biosci. 2009, 14, 1661–1683. [CrossRef]
115. Capra, M.L.; Del L Quiberoni, A.; Ackermann, H.W.; Moineau, S.; Reinheimer, J.A. Characterization of a new virulent phage (MLC-A) of Lactobacillus paracasei. J. Dairy Sci. 2006, 89, 2414–2423. [CrossRef]
116. Aucouturier, A.; Chain, F.; Langella, P.; Bidnenko, E. Characterization of a Prophage-Free Derivative Strain of Lactococcus lactis ssp. lactis IL1403 Reveals the Importance of Prophages for Phenotypic Plasticity of the Host. Front. Microbiol. 2018, 9, 2032. [CrossRef]
117. Waller, A.S.; Yamada, T.; Kristensen, D.M.; Kultima, J.R.; Sunagawa, S.; Koonin, E.V.; Bork, P. Classification and quantification of bacteriophage taxa in human gut metagenomes. ISME J. 2014, 8, 1391–1402. [CrossRef]
118. Visweswaran, G.R.; Kurek, D.; Szeliga, M.; Pastrana, F.R.; Kuipers, O.P.; Kok, J.; Buist, G. Expression of prophage-encoded endolysins contributes to autolysis of Lactococcus lactis. Appl. Microbiol. Biotechnol. 2017, 101, 1099–1110. [CrossRef]
119. Labrie, S.J.; Moineau, S. Abortive infection mechanisms and prophage sequences significantly influence the genetic makeup of emerging lytic lactococcal phages. J. Bacteriol. 2007, 189, 1482–1487. [CrossRef]
120. Chopin, M.C.; Chopin, A.; Bidnenko, E. Phage abortive infection in lactococci: Variations on a theme. Curr. Opin. Microbiol. 2005, 8, 473–479. [CrossRef]
121. Devirgiliis, C.; Zinno, P.; Perozzi, G. Update on antibiotic resistance in foodborne Lactobacillus and Lactococcus species. Front. Microbiol. 2013, 4, 301. [CrossRef]
122. Zhang, D.; Aravind, L. Novel transglutaminase-like peptidase and C2 domains elucidate the structure, biogenesis and evolution of the ciliary compartment. Cell Cycle 2012, 11, 3861–3875. [CrossRef]
123. Khan, S.H.; Ansari, F.A. Probiotics—The friendly bacteria with market potential in global market. Pak. J. Pharm. Sci. 2007, 20, 76–82.
124. Kopp-Hoolihan, L. Prophylactic and therapeutic uses of probiotics: A review. J. Am. Diet. Assoc. 2001, 101, 229–238. [CrossRef]
125. Kaur, I.P.; Chopra, K.; Saini, A. Probiotics: Potential pharmaceutical applications. Eur. J. Pharm. Sci. 2002, 15, 1–9. [CrossRef]
126. O’Toole, P.W.; Marchesi, J.R.; Hill, C. Next-generation probiotics: The spectrum from probiotics to live biotherapeutics. Nat. Microbiol. 2017, 2, 17057. [CrossRef]
127. Boesmans, L.; Valles-Colomer, M.; Wang, J.; Eeckhaut, V.; Falony, G.; Ducatelle, R.; van Immerseel, F.; Raes, J.; Verbeke, K. Butyrate Producers as Potential Next-Generation Probiotics: Safety Assessment of the Administration of Butyricicoccus pullicaecorum to Healthy Volunteers. mSystems 2018, e00094-18. [CrossRef]
128. Roman, P.; Estévez, A.F.; Miras, A.; Sánchez-Labraca, N.; Cañadas, F.; Vivas, A.B.; Cardona, D. A Pilot Randomized Controlled Trial to Explore Cognitive and Emotional Effects of Probiotics in Fibromyalgia. Sci. Rep. 2018, 8, 10965. [CrossRef]
129. Rezac, S.; Kok, C.R.; Heermann, M.; Hutkins, R. Fermented Foods as a Dietary Source of Live Organisms. Front. Microbiol. 2018, 9, 1785. [CrossRef]
130. Oniciuc, E.A.; Likotrafiti, E.; Alvarez-Molina, A.; Prieto, M.; Santos, J.A.; Alvarez-Ordóñez, A. The Present and Future of Whole Genome Sequencing (WGS) and Whole Metagenome Sequencing (WMS) for Surveillance of Antimicrobial Resistant Microorganisms and Antimicrobial Resistance Genes across the Food Chain. Genes 2018, 9, 268. [CrossRef]
131. Flórez, A.B.; Vázquez, L.; Mayo, B. A Functional Metagenomic Analysis of Tetracycline Resistance in Cheese Bacteria. Front. Microbiol. 2017, 8, 907. [CrossRef]
132. Glendinning, L.; Free, A. Supra-organismal interactions in the human intestine. Front. Cell. Infect. Microbiol. 2014, 4, 47. [CrossRef] [PubMed]
133. Devirgiliis, C.; Zinno, P.; Stirpe, M.; Barile, S.; Perozzi, G. Functional screening of antibiotic resistance genes from a representative metagenomic library of food fermenting microbiota. Biomed. Res. Int. 2014, 2014, 290967. [CrossRef]
134. Cole, M.L.; Singh, O.V. Microbial occurrence and antibiotic resistance in ready-to-go food items. J. Food Sci. Technol. 2018, 55, 2600–2609. [CrossRef]
135. Papagaroufalis, K.; Fotiou, A.; Egli, D.; Tran, L.A.; Steenhout, P. A Randomized Double Blind Controlled Safety Trial Evaluating d-Lactic Acid Production in Healthy Infants Fed a Lactobacillus reuteri-containing Formula. Nutr. Metab. Insights 2014, 7, 19–27. [CrossRef]
136. Haschke-Becher, E.; Brunser, O.; Cruchet, S.; Gotteland, M.; Haschke, F.; Bachmann, C. Urinary D-lactate excretion in infants receiving Lactobacillus johnsonii with formula. Ann. Nutr. Metab. 2008, 53, 240–244. [CrossRef]
137. Vitetta, L.; Coulson, S.; Thomsen, M.; Nguyen, T.; Hall, S. Probiotics, D-Lactic acidosis, oxidative stress and strain specificity. Gut Microbes 2017, 8, 311–322. [CrossRef]
138. Munakata, S.; Arakawa, C.; Kohira, R.; Fujita, Y.; Fuchigami, T.; Mugishima, H. A case of D-lactic acid encephalopathy associated with use of probiotics. Brain Dev. 2010, 32, 691–694. [CrossRef]
139. Rao, S.S.C.; Yu, S.; Tetangco, E.P.; Yan, Y. Probiotics can Cause D-Lactic Acidosis and Brain Fogginess: Reply to Quigley et al. Clin. Transl. Gastroenterol. 2018, 9, 207. [CrossRef]
140. Muñoz, J.A.; Chenoll, E.; Casinos, B.; Bataller, E.; Ramón, D.; Genovés, S.; Montava, R.; Ribes, J.M.; Buesa, J.; Fàbrega, J.; et al. Novel probiotic Bifidobacterium longum subsp. infantis CECT 7210 strain active against rotavirus infections. Appl. Environ. Microbiol. 2011, 77, 8775–8783. [CrossRef]
141. Ewaschuk, J.B.; Naylor, J.M.; Zello, G.A. D-lactate in human and ruminant metabolism. J. Nutr. 2005, 135, 1619–1625. [CrossRef]
142. Ku, W.H.; Lau, D.C.Y.; Huen, K.F. Probiotics Provoked D-lactic Acidosis in Short Bowel Syndrome: Case Report and Literature. HK J. Paediatr. 2006, 11, 246–254.
143. Petersen, C. D-lactic acidosis. Nutr. Clin. Pract. 2005, 20, 634–645. [CrossRef]
144. Uribarri, J.; Oh, M.S.; Carroll, H.J. D-lactic acidosis. A review of clinical presentation, biochemical features, and pathophysiologic mechanisms. Medicine 1998, 77, 73–82. [CrossRef]
145. Oh, M.S.; Phelps, K.R.; Traube, M.; Barbosa-Saldivar, J.L.; Boxhill, C.; Carroll, H.J. D-lactic acidosis in a man with the short-bowel syndrome. N. Engl. J. Med. 1979, 301, 249–252. [CrossRef]
146. Quigley, E.M.M.; Pot, B.; Sanders, M.E. ‘Brain Fogginess’ and D-Lactic Acidosis: Probiotics Are Not the Cause. Clin. Transl. Gastroenterol. 2018, 9, 187. [CrossRef]
147. Sachdeva, S.; Puri, A.S.; Kumar, A.; Dalal, A.; Dahale, A.S. Brain Fogginess and SIBO: A Link or Just a Mirage? Clin. Transl. Gastroenterol. 2018, 9, 184. [CrossRef]
148. Van den Nieuwboer, M.; Brummer, R.J.; Guarner, F.; Morelli, L.; Cabana, M.; Claasen, E. The administration of probiotics and synbiotics in immune compromised adults: Is it safe? Benef. Microbes 2015, 6, 3–17. [CrossRef]
149. Sanders, M.E.; Akkermans, L.M.; Haller, D.; Hammerman, C.; Heimbach, J.; Hörmannsperger, G.; Huys, G. Safety assessment of probiotics for human use. Gut Microbes 2010, 1, 164–185. [CrossRef]
150. Sherid, M.; Samo, S.; Sulaiman, S.; Husein, H.; Sifuentes, H.; Sridhar, S. Liver abscess and bacteremia caused by lactobacillus: Role of probiotics? Case report and review of the literature. BMC Gastroenterol. 2016, 16, 138. [CrossRef]
151. Kopp, M.V.; Hennemuth, I.; Heinzmann, A.; Urbanek, R. Randomized, double-blind, placebo-controlled trial of probiotics for primary prevention: no clinical effects of Lactobacillus GG supplementation. Pediatrics 2008, 121, e850-6. [CrossRef]
152. Franz, C.M.; Muscholl-Silberhorn, A.B.; Yousif, N.M.; Vancanneyt, M.; Swings, J.; Holzapfel, W.H. Incidence of virulence factors and antibiotic resistance among Enterococci isolated from food. Appl. Environ. Microbiol. 2001, 67, 4385–4389. [CrossRef]
153. Rathnayake, I.U.; Hargreaves, M.; Huygens, F. Antibiotic resistance and virulence traits in clinical and environmental Enterococcus faecalis and Enterococcus faecium isolates. Syst. Appl. Microbiol. 2012, 35, 326–333. [CrossRef]
154. Kho, Z.Y.; Lal, S.K. The Human Gut Microbiome—A Potential Controller of Wellness and Disease. Front. Microbiol. 2018, 9, 1835. [CrossRef]
155. Glendinning, L.; Free, A. Supra-organismal interactions in the human intestine. Front. Cell. Infect. Microbiol. 2014, 4, 47. [CrossRef] [PubMed]
156. Naqvi, S.S.B.; Nagendra, V.; Hofmeyr, A. Probiotic related Lactobacillus rhamnosus endocarditis in a patient with liver cirrhosis. IDCases 2018, 13, e00439. [CrossRef]
157. Boumis, E.; Capone, A.; Galati, V.; Venditti, C.; Petrosillo, N. Probiotics and infective endocarditis in patients with hereditary hemorrhagic telangiectasia: A clinical case and a review of the literature. BMC Infect. Dis. 2018, 18, 65. [CrossRef]
158. Jäsberg, H.; Tervahartiala, T.; Sorsa, T.; Söderling, E.; Haukioja, A. Probiotic intervention influences the salivary levels of Matrix Metalloproteinase (MMP)-9 and Tissue Inhibitor of metalloproteinases (TIMP)-1 in healthy adults. Arch. Oral Biol. 2018, 85, 58–63. [CrossRef]
159. Falcinelli, S.; Rodiles, A.; Hatef, A.; Picchietti, S.; Cossignani, L.; Merrifield, D.L.; Unniappan, S.; Carnevali, O. Influence of Probiotics Administration on Gut Microbiota Core: A Review on the Effects on Appetite Control, Glucose, and Lipid Metabolism. J. Clin. Gastroenterol. 2018, 52 (Suppl. 1), S50–S56. [CrossRef]
160. Dufour, A.; Hindré, T.; Haras, D.; Le Pennec, J.P. The biology of lantibiotics from the lacticin 481 group is coming of age. FEMS Microbiol. Rev. 2007, 31, 134–167. [CrossRef]
161. Muthu Selvam, R.; Vinothini, G.; Palliyarai Thaiyammal, S.; Latha, S.; Chinnathambi, A.; Dhanasekaran, D.; Padmanabhan, P.; Alharbi, S.A.; Archunan, G. The cell aggregating propensity of probiotic actinobacterial isolates: Isolation and characterization of the aggregation inducing peptide pheromone. Biofouling 2016, 32, 71–79. [CrossRef]
162. Kitazawa, H.; Ino, T.; Kawai, Y.; Itoh, T.; Saito, T. A novel immunostimulating aspect of Lactobacillus gasseri: Induction of “Gasserokine” as chemoattractants for macrophages. Int. J. Food Microbiol. 2002, 77, 29–38. [CrossRef]
163. Nagy, G.; Pinczes, G.; Pinter, G.; Pocsi, I.; Prokisch, J.; Banfalvi, G. In Situ Electron Microscopy of Lactomicroselenium Particles in Probiotic Bacteria. Int. J. Mol. Sci. 2016, 17, 1047. [CrossRef]
164. Washington, E.J.; Banfield, M.J.; Dangl, J.L. What a difference a Dalton makes: Bacterial virulence factors modulate eukaryotic host cell signaling systems via deamidation. Microbiol. Mol. Biol. Rev. 2013, 77, 527–539. [CrossRef]
165. Rondanelli, M.; Faliva, M.A.; Perna, S.; Giacosa, A.; Peroni, G.; Castellazzi, A.M. Using probiotics in clinical practice: Where are we now? A review of existing meta-analyses. Gut Microbes 2017, 8, 521–543. [CrossRef]
166. Hempel, S.; Newberry, S.; Ruelaz, A.; Wang, Z.; Miles, J.N.; Suttorp, M.J.; Johnsen, B.; Shanman, R.; Slusser, W.; Fu, N.; et al. Safety of probiotics used to reduce risk and prevent or treat disease. Evid. Rep. Technol. Assess. 2011, 200, 1–645.
167. van den Nieuwboer, M.; Brummer, R.J.; Guarner, F.; Morelli, L.; Cabana, M.; Claassen, E. Safety of probiotics and synbiotics in children under 18 years of age. Benef. Microbes 2015, 6, 615–630. [CrossRef]
168. Doherty, G.A.; Bennett, G.C.; Cheifetz, A.S.; Moss, A.C. Meta-analysis: Targeting the intestinal microbiota in prophylaxis for post-operative Crohn’s disease. Aliment. Pharmacol. Ther. 2010, 31, 802–809. [CrossRef]
169. Tan-Lim, C.S.C.; Esteban-Ipac, N.A.R. Probiotics as treatment for food allergies among pediatric patients: A meta-analysis. World Allergy Organ. J. 2018, 11, 25. [CrossRef]
170. Osborn, D.A.; Sinn, J.K. Probiotics in infants for prevention of allergic disease and food hypersensitivity. Cochrane Database Syst. Rev. 2007, 4, CD006475. [CrossRef]
171. Reis, D.J.; Ilardi, S.S.; Punt, S.E.W. The anxiolytic effect of probiotics: A systematic review and meta-analysis of the clinical and preclinical literature. PLoS ONE 2018, 13, e0199041. [CrossRef]
172. Borgeraas, H.; Johnson, L.K.; Skattebu, J.; Hertel, J.K.; Hjelmesaeth, J. Effects of probiotics on body weight, body mass index, fat mass and fat percentage in subjects with overweight or obesity: A systematic review and meta-analysis of randomized controlled trials. Obes. Rev. 2018, 19, 219–232. [CrossRef]
173. Wardill, H.R.; Van Sebille, Y.Z.A.; Ciorba, M.A.; Bowen, J.M. Prophylactic probiotics for cancer therapy-induced diarrhoea: A meta-analysis. Curr. Opin. Support Palliat. Care 2018, 12, 187–197. [CrossRef]
174. Canales, J.; Rada, G. Are probiotics effective in preventing urinary tract infection? Medwave 2018, 18, e7186. [CrossRef]
175. Hassan, H.; Rompola, M.; Glaser, A.W.; Kinsey, S.E.; Phillips, R.S. Systematic review and meta-analysis investigating the efficacy and safety of probiotics in people with cancer. Support Care Cancer 2018, 26, 2503–2509. [CrossRef]
176. Mohammed, A.T.; Khattab, M.; Ahmed, A.M.; Turk, T.; Sakr, N.; Khalil, A.M.; Abdelhalim, M.; Sawaf, B.; Hirayama, K.; Huy, N.T. The therapeutic effect of probiotics on rheumatoid arthritis: A systematic review and meta-analysis of randomized control trials. Clin. Rheumatol. 2017, 36, 2697–2707. [CrossRef]
177. Liu, B.; He, Y.; Wang, M.; Liu, J.; Ju, Y.; Zhang, Y.; Liu, T.; Li, L.; Li, Q. Efficacy of probiotics on anxiety-A meta-analysis of randomized controlled trials. Depress Anxiety 2018, 35, 935–945. [CrossRef]
178. Lin, J.; Zhang, Y.; He, C.; Dai, J. Probiotics supplementation in children with asthma: A systematic review and meta-analysis. J. Paediatr. Child Health 2018, 54, 953–961. [CrossRef]
179. McFarland, L.V.; Goh, S. Are probiotics and prebiotics effective in the prevention of travellers’ diarrhea: A systematic review and meta-analysis. Travel Med. Infect Dis. 2018. [CrossRef]
180. Jin, L.; Deng, L.; Wu, W.; Wang, Z.; Shao, W.; Liu, J. Systematic review and meta-analysis of the effect of probiotic supplementation on functional constipation in children. Medicine 2018, 97, e12174. [CrossRef]
181. Rouhani, M.H.; Hadi, A.; Ghaedi, E.; Salehi, M.; Mahdavi, A.; Mohammadi, H. Do probiotics, prebiotics and synbiotics affect adiponectin and leptin in adults? A systematic review and meta-analysis of clinical trials. Clin. Nutr. 2018. [CrossRef]
182. Upadhyay, R.P.; Taneja, S.; Chowdhury, R.; Strand, T.A.; Bhandari, N. Effect of prebiotic and probiotic supplementation on neurodevelopment in preterm very low birth weight infants: Findings from a meta-analysis. Pediatr. Res. 2018. [CrossRef]
183. Dalal, R.; McGee, R.G.; Riordan, S.M.; Webster, A.C. Probiotics for people with hepatic encephalopathy. Cochrane Database Syst. Rev. 2017, 2, CD008716. [CrossRef]
184. Goldenberg, J.Z.; Lytvyn, L.; Steurich, J.; Parkin, P.; Mahant, S.; Johnston, B.C. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst. Rev. 2015, 12, CD004827. [CrossRef]
185. Szajewska, H.; Horvath, A. Lactobacillus rhamnosus GG in the Primary Prevention of Eczema in Children: A Systematic Review and Meta-Analysis. Nutrients 2018, 10, 1319. [CrossRef]
186. Mater, D.D.; Langella, P.; Corthier, G.; Flores, M.J. A probiotic Lactobacillus strain can acquire vancomycin resistance during digestive transit in mice. J. Mol. Microbiol. Biotechnol. 2008, 14, 123–127. [CrossRef]
187. Jalali, M.; Abedi, D.; Varshosaz, J.; Najjarzadeh, M.; Mirlohi, M.; Tavakoli, N. Stability evaluation of freeze-dried Lactobacillus paracasei subsp. tolerance and Lactobacillus delbrueckii subsp. bulgaricus in oral capsules. Res Pharm Sci. 2012, 7, 31–36.
188. Generally Recognized as Safe (GRAS). Available online: http://www.fda.gov/food/IngredientspackagingLabeling/GRAS/(accessed on 7February 2019).
189. Glendinning, L.; Free, A. Supra-organismal interactions in the human intestine. Front. Cell. Infect. Microbiol. 2014, 4, 47. [CrossRef] [PubMed]
190. Duc, L.H.; Hong, H.A.; Barbosa, T.M.; Henriques, A.O.; Cutting, S.M. Characterization of Bacillus probiotics available for human use. Appl. Environ. Microbiol. 2004, 70, 2161–2171. [CrossRef]
191. Green, D.H.; Wakeley, P.R.; Page, A.; Barnes, A.; Baccigalupi, L.; Ricca, E.; Cutting, S.M. Characterization of two Bacillus probiotics. Appl. Environ. Microbiol. 1999, 65, 4288–4291.
192. Temmerman, R.; Scheirlinck, I.; Huys, G.; Swings, J. Culture-independent analysis of probiotic products by denaturing gradient gel electrophoresis. Appl. Environ. Microbiol. 2003, 69, 220–226. [CrossRef]
193. Masco, L.; Huys, G.; De Brandt, E.; Temmerman, R.; Swings, J. Culture-dependent and culture-independent qualitative analysis of probiotic products claimed to contain bifidobacteria. Int. J. Food Microbiol. 2005, 102, 221–230. [CrossRef]
194. Ouwehand, A.C. A review of dose-responses of probiotics in human studies. Benef. Microbes 2017, 8, 143–151. [CrossRef]
195. Hoffmann, D.E. Health claim regulation of probiotics in the USA and the EU: Is there a middle way? Benef. Microbes 2013, 4, 109–115. [CrossRef]
196. Lee, T.T.; Morisset, M.; Astier, C.; Moneret-Vautrin, D.A.; Cordebar, V.; Beaudouin, E.; Codreanu, F.; Bihain, B.E.; Kanny, G. Contamination of probiotic preparations with milk allergens can cause anaphylaxis in children with cow’s milk allergy. J. Allergy Clin. Immunol. 2007, 119, 746–747.
197. Martín-Muñoz, M.F.; Fortuni, M.; Caminoa, M.; Belver, T.; Quirce, S.; Caballero, T. Anaphylactic reaction to probiotics. Cow’s milk and hen’s egg allergens in probiotic compounds. Pediatr. Allergy Immunol. 2012, 23, 778–784. [CrossRef]
198. Allen, E.N.; Chandler, C.I.; Mandimika, N.; Leisegang, C.; Barnes, K. Eliciting adverse effects data from participants in clinical trials. Cochrane Database Syst. Rev. 2018, 1, MR000039. [CrossRef]
199. Jin, Y.; Sanger, N.; Shams, I.; Luo, C.; Shahid, H.; Li, G.; Bhatt, M.; Zielinski, L.; Bantoto, B.; Wang, M.; et al. Does the medical literature remain inadequately described despite having reporting guidelines for 21 years?—A systematic review of reviews: An update. J. Multidiscip. Healthc. 2018, 11, 495–510. [CrossRef]
200. Bafeta, A.; Koh, M.; Riveros, C.; Ravaud, P. Harms Reporting in Randomized Controlled Trials of Interventions Aimed at Modifying Microbiota: A Systematic Review. Ann. Intern. Med. 2018, 169, 240–247. [CrossRef]
201. van den Nieuwboer, M.; Claassen, E.; Morelli, L.; Guarner, F.; Brummer, R.J. Probiotic and synbiotic safety in infants under two years of age. Benef. Microbes 2014, 5, 45–60. [CrossRef]
202. Mugambi, M.N.; Musekiwa, A.; Lombard, M.; Young, T.; Blaauw, R. Association between funding source, methodological quality and research outcomes in randomized controlled trials of synbiotics, probiotics and prebiotics added to infant formula: A systematic review. BMC Med. Res. Methodol. 2013, 13, 137. [CrossRef]
203. Aceti, A.; Beghetti, I.; Maggio, L.; Martini, S.; Faldella, G.; Corvaglia, L. Filling the Gaps: Current Research Directions for a Rational Use of Probiotics in Preterm Infants. Nutrients 2018, 10, 1472. [CrossRef]
204. Huff, B.A. Caveat emptor. “Probiotics” might not be what they seem. Can. Fam. Physician 2004, 50, 583–587.
205. Sanders, M. How do we know when something called” probiotic” is really a probiotic? A guideline for consumers and healthcare professionals. Funct. Food Rev. 2009, 1, 3–12.
206. Sanders, M.E.; Klaenhammer, T.R.; Ouwehand, A.C.; Pot, B.; Johansen, E.; Heimbach, J.T.; Marco, M.L.; Tennilä, J.; Ross, R.P.; Franz, C.; et al. Effects of genetic, processing, or product formulation changes on efficacy and safety of probiotics. Ann. N. Y. Acad. Sci. 2014, 1309, 1–18. [CrossRef]
207. Katan, M.B. Why the European Food Safety Authority was right to reject health claims for probiotics. Benef. Microbes 2012, 3, 85–89. [CrossRef]
208. Smug, L.N.; Salminen, S.; Sanders, M.E.; Ebner, S. Yoghurt and probiotic bacteria in dietary guidelines of the member states of the European Union. Benef. Microbes 2014, 5, 61–66. [CrossRef]
209. Dronkers, T.M.G.; Krist, L.; Van Overveld, F.J.; Rijkers, G.T. The ascent of the blessed: Regulatory issues on health effects and health claims for probiotics in Europe and the rest of the world. Benef. Microbes 2018, 9, 717–723. [CrossRef]
210. Glendinning, L.; Free, A. Supra-organismal interactions in the human intestine. Front. Cell. Infect. Microbiol. 2014, 4, 47. [CrossRef] [PubMed]
211. Ebner, S.; Smug, L.N.; Kneifel, W.; Salminen, S.J.; Sanders, M.E. Probiotics in dietary guidelines and clinical recommendations outside the European Union. World J. Gastroenterol. 2014, 20, 16095–16100. [CrossRef]
212. Lee, E.S.; Song, E.J.; Nam, Y.D.; Lee, S.Y. Probiotics in human health and disease: From nutribiotics to pharmabiotics. J. Microbiol. 2018, 56, 773–782. [CrossRef]
213. Azad, M.A.K.; Sarker, M.; Li, T.; Yin, J. Probiotic Species in the Modulation of Gut Microbiota: An Overview. Biomed. Res. Int. 2018, 2018, 9478630. [CrossRef]